Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Unknown 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6Observational 4

Sponsor

Cancer Type

Breast 6CNS 1

Conditions

Breast Neoplasms 10180Triple Negative Breast Neoplasms 1045Neoplasms 573Ovarian Neoplasms 564Neoplasm Metastasis 515Colorectal Neoplasms 472Carcinoma, Non-Small-Cell Lung 467Prostatic Neoplasms 440Lung Neoplasms 433Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 295Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 227Endometrial Neoplasms 223Head and Neck Neoplasms 218Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 192Squamous Cell Carcinoma of Head and Neck 181Sarcoma 176Urinary Bladder Neoplasms 159Esophageal Neoplasms 155Brain Neoplasms 155Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 130

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2tucatinib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Fulvestrant 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × HER2-positive Metastatic Breast Cancer × Breast × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Jiangxi Provincial Cancer Hospital

Phase 2 Unknown
362 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
338 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡